Bacteria used as factories to produce cancer drugs

Researchers at the Novo Nordisk Foundation Center for Biosustainability in Denmark have developed a method of producing P450 enzymes - used by plants to defend against predators and microbes - in bacterial cell factories. The process could facilitate the production of large quantities of the enzymes, which are also involved in the biosynthesis of active ingredients of cancer drugs.

P450 is the name of a type of cytochrome, a specialised enzyme. These are used by plants to synthesise chemical compounds with many different functions, but their main use is in defending against herbivores, insects and microbes.

"These powerful compounds can be used as active ingredients in drugs for treating diseases such as cancer and psoriasis," SINC was told by the Spanish researcher Darío Vázquez-Albacete, the lead author of a paper describing a new method of producing the enzymes in bacterial cell factories.

The findings of the study, developed at the Novo Nordisk Foundation Center for Biosustainability, a research facility managed by the Technical University of Denmark, were published in the journal Biotechnology and Bioengineering.

According to Vázquez-Albacete, "the new technique is a significant step forward, as plants produce P450 enzymes in very small amounts, extraction is very complex and sometimes we have to use polluting chemical synthesis processes which involve the use of oil derivatives. Additionally, some plant species such as the yew (Taxus baccata), from which the cancer drug Taxol is obtained, are endangered species."

Large-scale production
"We have developed tools which will allow the proteins from plants that produce these compounds to be recognized by the bacterial molecular machinery. The aim is to use bacteria because they arecapable of growing rapidly in controlled fermenters, allowing us to produce large quantities of the enzymes," says the researcher.

To achieve these results, the researchers modified and transferred P450 genes from plants to E. Coli bacteria and to check whether the microbes could produce larger quantities of these enzymes than existing methods.

Vázquez-Albacete says that "in order for the bacteria to properly express the enzymes, the corresponding DNA sequence must frequently be modified to facilitate 'decoding' by the bacteria's system."

In the study, the team developed a toolbox of 'auxiliary' DNA sequences, allowing them to express around 50 P450 enzymes from different plants in E. coli.

Some of these enzymes are involved in synthesising the natural compound ingenol, which is used to treat psoriasis and is currently manufactured using traditional chemical techniques. Other P450s are used to produce the cancer drug Taxol.

The researcher stresses that plants generate a variety of interesting compounds to protect them from the sun and from predators, dehydration, etc. "Many of these are synthesised by P450s, whose function is still very little understood, so there is enormous potential to discover new compounds."

Besides the Novo Nordisk Foundation team, a handful of other groups are already following this line of research. Pharmaceutical firms have already displayed interest in the new technique.

Vazquez-Albacete D, Cavaleiro AM, Christensen U, Seppälä S, Møller BL, Nørholm MH.
An expression tag toolbox for microbial production of membrane bound plant cytochromes P450.
Biotechnol Bioeng. 2017 Apr;114(4):751-760. doi: 10.1002/bit.26203.

Most Popular Now

A need for bananas? Dietary potassium regulates ca…

Bananas and avocados - foods that are rich in potassium - may help protect against pathogenic vascular calcification, also known as hardening of the arteries. University ...

FDA awards 15 grants for clinical trials to stimul…

The U.S. Food and Drug Administration today announced that it has awarded 15 new clinical trial research grants totaling more than $22 million over the next four years to...

Amgen and CytomX Therapeutics announce strategic c…

Amgen (NASDAQ:AMGN) and CytomX Therapeutics, Inc., (NASDAQ:CTMX) today announced that the companies have entered into a strategic collaboration in immuno-oncology. The co...

Novartis and The Max Foundation transform pioneeri…

Novartis announced a new collaboration with The Max Foundation to support continued access to treatment at no cost for nearly 34,000 current patients with chronic myeloid...

Roche launches NAVIFY Tumor Board solution to prov…

Roche (SIX: RO, ROG; OTCQX:RHHBY), has announced the launch of the NAVIFY Tumor Board solution, a clinical workflow and decision support software that optimises decision-...

AbbVie and Bristol-Myers Squibb announce clinical …

AbbVie (NYSE: ABBV) and Bristol-Myers Squibb Company (NYSE: BMY) today announced a clinical trial collaboration to evaluate the combination of AbbVie's investigational an...

Tagrisso granted breakthrough therapy designation …

AstraZeneca announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for Tagrisso (osimertinib) for the 1st-line treatm...

Pfizer launches novel programs to put important su…

Pfizer today unveils enhanced offerings to help patients manage their life with cancer. Pfizer Oncology Together is a first-of-its-kind program for patients taking Pfizer...

Novartis and UC Berkeley collaborate to tackle 'un…

Novartis has joined forces with researchers from the University of California, Berkeley, to develop new technologies for the discovery of next-generation therapeutics, pu...

Printed meds could reinvent pharmacies, drug resea…

A technology that can print pure, ultra-precise doses of drugs onto a wide variety of surfaces could one day enable on-site printing of custom-dosed medications at pharma...

Danish discovery can pave the way for more effecti…

More than 600,000 Danes are being treated with cholesterol lowering medicine. 98 per cent of them are treated with statins, which curb the body's own production of choles...

Amgen and Simcere announce strategic collaboration…

Amgen (NASDAQ: AMGN) and Simcere Pharmaceutical Group have announced the execution of an exclusive agreement to co-develop and commercialize four biosimilars in China. Th...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]